Company news

Clinuvel Pharmaceuticals Limited news in 2024

Clinuvel Pharmaceuticals Limited's news releases, calls and decks from 2024, newest first.

View company

Health Canada validates SCENESSE New Drug Submission

December 22, 2024

Chair's letter to Shareholders

December 4, 2024

SCENESSE dosage expansion under review by EMA

November 19, 2024

CLINUVEL prioritises three strategic programs

November 17, 2024

Managing Director Presentation

October 15, 2024

Canadian New Drug Submission for SCENESSE in EPP filed

September 30, 2024

CLINUVEL delivers increases in annual revenue, profit

August 28, 2024

Appendix 4E and Annual Report to Shareholders 2024

August 28, 2024

Vitiligo and Operational Update

August 20, 2024

Afamelanotide Assists DNA Repair Response Following UVR

July 5, 2024

CLINUVEL extends Managing Director Employment Agreement

June 28, 2024

afamelanotide in fair-skinned Parkinsons patients

June 17, 2024

CLINUVEL initiates on market share buy-back program

March 14, 2024

New case of SCENESSE efficacy in vitiligo presented at AAD

March 10, 2024

SCENESSE provides photoprotection in variegate porphyria

March 3, 2024

CUV Appendix 4D Half Year Report

February 21, 2024

Decks in 2024